查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2021658

個人化癌症治療和免疫療法市場預測——治療方法、生物標記、癌症類型、技術、最終用戶和地區分類的全球分析——2034年

Personalized Oncology & Immunotherapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Biomarker, Cancer Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

全球個人化癌症治療和免疫療法市場預計到 2026 年將達到 1800 億美元，並在預測期內以 11% 的複合年成長率成長，到 2034 年達到 4200 億美元。

個人化癌症治療和免疫療法根據每位患者的基因譜、腫瘤特徵和免疫系統反應來最佳化癌症治療。這種方法包括標靶治療、免疫查核點抑制劑和細胞療法，旨在增強人體對癌症的抵抗力。透過專注於精準醫療，這些治療方法能夠提高療效並減少副作用。基因組學、生物標記和診斷技術的進步正在推動該領域的創新，使癌症患者能夠選擇更精準的治療方法方案並獲得更好的臨床療效。

全球癌症發生率不斷上升

肺癌、乳癌和大腸癌發生率的上升導致對先進治療方法的需求激增。個人化醫療使臨床醫生能夠根據患者的基因、分子和免疫學特徵量身定做治療方法，從而提高療效並減少副作用。免疫療法，包括免疫查核點抑制劑和CAR-T療法，因其在對傳統療法抗藥性的患者中展現出的持續療效而備受關注。日益沉重的全球癌症負擔正在加速對精準醫療和生物標記主導型研究的投資。醫療保健系統正將個人化癌症治療置於優先地位，以提高存活率並降低醫療成本。

個人化醫療高成本

精準腫瘤學和免疫療法通常涉及複雜的診斷檢測、先進的生物製藥和個人化治療方法，所有這些都會推高成本。許多醫療系統，尤其是在發展中地區，由於報銷機制有限，難以提供廣泛的醫療服務。患者面臨經濟負擔，自付費用成為接受治療的一大障礙。製藥公司面臨著在創新和價格可負擔性之間取得平衡的壓力，但定價仍然是一個挑戰。儘管目前正在進行研究，透過可擴展的生產和改進的診斷技術來降低成本，但價格可負擔性問題仍然存在。

標靶免疫療法的發展

基因組學和蛋白​​質組學的進步使得識別新的生物標記和治療標靶成為可能。單株抗體、癌症疫苗和基因改造T細胞療法等免疫療法正日益根據患者的個別情況進行客製化。與傳統化療相比，這些方法具有更高的療效和更低的毒性。製藥公司正大力投資合作研發，以加速該領域的創新。監管機構也支持突破性治療方法的快速核准，進一步提升了市場潛力。

與傳統癌症治療方法的競爭

由於化療、放射線治療和手術療效顯著且成本低廉，它們在許多地區仍然是標準的治療方案。醫生和患者可能對採用更新、更昂貴的個人化療法猶豫不決，因為缺乏長期療效證據。在資源匱乏的環境中，傳統療法因其價格低廉且易於取得而佔據主導地位。這種對傳統療法的持續依賴可能會阻礙個人化癌症治療方案的推廣。克服這項挑戰需要可靠的臨床數據、成本效益研究以及提高醫療專業人員的認知。

新冠疫情的影響：

新冠疫情對個人化癌症治療和免疫療法市場產生了複雜的影響。一方面，臨床試驗和供應鏈的中斷延緩了新治療方法的研發和交付。許多癌症患者由於醫院資源有限而被迫中斷治療。另一方面，疫情加速了數位醫療和遠距遠端醫療的普及，支持了遠端患者監護和個人化照護的提供。製藥公司透過利用分散式臨床試驗和數位平台繼續進行研究，從而適應了這種情況。隨著疫情後的復甦，腫瘤研發領域的投資重新燃起，個人化免疫療法也重獲發展動力。

在預測期內，肺癌領域預計將佔據最大的市場佔有率。

在預測期內，肺癌領域預計將佔據最大的市場佔有率。這是因為，隨著全球癌症發生率的不斷上升，肺癌已成為個人化治療研發最為迫切的領域之一。肺癌仍然是全球癌症相關死亡的主要原因，推動了對創新治療方法的需求。包括基於生物標記的標靶治療和免疫療法在內的個人化治療方法正被擴大採用，以提高存活率。液態生物檢體和基因測序等診斷技術的進步正在加速早期檢測和個人化治療。由於肺癌帶來的巨大臨床和經濟負擔，製藥公司正致力於開發肺癌相關產品線。

在預測期內，癌症研究機構細分市場預計將呈現最高的複合年成長率。

在預測期內，受全球癌症發病率上升以及由此產生的對個人化醫療領域先進研發和創新需求的推動，癌症研究機構預計將呈現最高的成長率。研究機構在生物標記發現、免疫療法開發和精準診斷方面主導。與製藥公司和政府機構的合作正在加速臨床試驗的發展。研究機構在培養腫瘤學家和傳播個人化醫療方法方面也發揮著至關重要的作用。隨著癌症發生率的上升，研究機構將繼續處於創新前沿，並推動快速成長。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其先進的醫療基礎設施和全球癌症發病率的上升，推動了對個人化癌症治療方案日益成長的需求。美國在精準醫療的推廣應用方面處於主導地位，這得益於其強大的研發投入和優惠的健保政策。該地區聚集了許多大型製藥公司和研究機構，推動創新發展。美國食品藥物管理局（FDA）等監管機構對突破性治療方法提供快速核准，進一步促進了精準醫療的普及。在持續創新和強勁的醫療保健支出支持下，該地區的領先地位預計將繼續保持。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健的快速數位化以及全球癌症發病率的上升，尤其是在新興經濟體。中國、印度和日本等國的癌症發生率不斷上升，使得精準醫療的需求日益迫切。各國政府正在加大對腫瘤基礎設施的投入，並支持臨床研究工作。本地研究機構與全球製藥公司之間的合作日益密切，加速了創新進程。可支配收入的增加和醫療服務可近性的提高，促使更多患者接受先進治療方法。此外，該地區也受益於人們對精準醫療和免疫療法日益成長的關注。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球個人化癌症治療與免疫療法市場：依治療方法

  • 免疫查核點抑制劑
  • CAR-T細胞療法
  • 癌症疫苗
  • 單株抗體
  • 標靶小分子療法
  • 其他治療方法

第6章 全球個人化癌症治療與免疫治療市場：依生物標記分類

  • 基因生物標記
  • 蛋白質體學生物標記
  • 腫瘤突變負荷（TMB）
  • PD-L1表達
  • 其他生物標記

第7章 全球個人化癌症治療與免疫治療市場：依癌症類型分類

  • 肺癌
  • 乳癌
  • 結腸癌
  • 黑色素瘤
  • 血癌
  • 其他癌症

第8章 全球個人化癌症治療和免疫療法市場：按技術分類

  • 次世代定序（NGS）
  • 基於PCR的檢測
  • 流式細胞技術
  • 基因編輯技術
  • 其他技術

第9章 全球個人化癌症治療和免疫療法市場：按最終用戶分類

  • 醫院
  • 癌症研究機構
  • 專科腫瘤診所
  • 診斷檢查室
  • 其他最終用戶

第10章 全球個人化癌症治療和免疫療法市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Roche Holding AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Regeneron Pharmaceuticals
  • BeiGene Ltd.
  • Moderna Inc.
  • BioNTech SE
  • Iovance Biotherapeutics
  • Bluebird Bio Inc.
  • Kite Pharma
Product Code: SMRC35101

According to Stratistics MRC, the Global Personalized Oncology & Immunotherapy Market is accounted for $180 billion in 2026 and is expected to reach $420 billion by 2034 growing at a CAGR of 11% during the forecast period. Personalized Oncology & Immunotherapy involves tailoring cancer treatment based on an individual patient's genetic profile, tumor characteristics, and immune system response. This approach includes targeted therapies, immune checkpoint inhibitors, and cell-based treatments designed to enhance the body's ability to fight cancer. By focusing on precision medicine, these therapies improve treatment effectiveness and reduce side effects. Advances in genomics, biomarkers, and diagnostics are driving innovation in this field, enabling more accurate treatment selection and better clinical outcomes for cancer patients.

Market Dynamics:

Driver:

Rising cancer prevalence globally

Increasing incidence of cancers such as lung, breast, and colorectal is creating urgent demand for advanced treatment options. Personalized therapies allow clinicians to tailor interventions based on genetic, molecular, and immunological profiles, improving efficacy and reducing side effects. Immunotherapy approaches, including checkpoint inhibitors and CAR-T therapies, are gaining traction as they offer durable responses in patients resistant to conventional treatments. The growing burden of cancer worldwide has accelerated investments in precision medicine and biomarker-driven research. Healthcare systems are prioritizing personalized oncology to improve survival rates and reduce healthcare costs.

Restraint:

High cost of personalized treatments

Precision oncology and immunotherapy often involve complex diagnostic tests, advanced biologics, and customized treatment regimens, all of which drive up expenses. Many healthcare systems, particularly in developing regions, struggle to provide widespread access due to limited reimbursement frameworks. Patients face financial toxicity, with out-of-pocket costs becoming a barrier to adoption. Pharmaceutical companies are under pressure to balance innovation with affordability, but pricing remains a challenge. While ongoing research aims to reduce costs through scalable manufacturing and improved diagnostics, affordability issues persist.

Opportunity:

Development of targeted immunotherapies

Advances in genomics and proteomics are enabling the identification of novel biomarkers and therapeutic targets. Immunotherapies such as monoclonal antibodies, cancer vaccines, and engineered T-cell therapies are increasingly being tailored to individual patient profiles. These approaches offer improved efficacy and reduced toxicity compared to traditional chemotherapy. Pharmaceutical companies are investing heavily in R&D collaborations to accelerate innovation in this space. Regulatory agencies are also supporting fast-track approvals for breakthrough therapies, enhancing market potential.

Threat:

Competition from conventional cancer therapies

Chemotherapy, radiation, and surgery remain the standard of care in many regions due to their established efficacy and lower costs. Physicians and patients may be hesitant to adopt newer, more expensive personalized treatments without long-term evidence of superiority. In resource-constrained settings, conventional therapies continue to dominate due to affordability and accessibility. This entrenched reliance on traditional approaches can slow the uptake of personalized oncology solutions. Overcoming this threat requires robust clinical data, cost-effectiveness studies, and greater awareness among healthcare providers.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the personalized oncology and immunotherapy market. On one hand, disruptions in clinical trials and supply chains delayed the development and delivery of new therapies. Many cancer patients experienced treatment interruptions due to hospital resource constraints. On the other hand, the pandemic accelerated adoption of digital health and telemedicine, supporting remote patient monitoring and personalized care delivery. Pharmaceutical companies adapted by leveraging decentralized trials and digital platforms to continue research. Post-pandemic recovery has reignited investments in oncology R&D, with personalized immunotherapies regaining momentum.

The lung cancer segment is expected to be the largest during the forecast period

The lung cancer segment is expected to account for the largest market share during the forecast period as rising cancer prevalence globally has made lung cancer one of the most urgent areas for personalized treatment development. Lung cancer remains the leading cause of cancer-related deaths worldwide, driving demand for innovative therapies. Personalized approaches, including biomarker-driven targeted therapies and immunotherapies, are increasingly being adopted to improve survival rates. Advances in diagnostics such as liquid biopsies and genomic sequencing are enhancing early detection and treatment personalization. Pharmaceutical companies are focusing heavily on lung cancer pipelines due to its high clinical and economic burden.

The cancer research institutes segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cancer research institutes segment is predicted to witness the highest growth rate due to rising cancer prevalence globally, which has intensified demand for advanced research and innovation in personalized therapies. Institutes are leading efforts in biomarker discovery, immunotherapy development, and precision diagnostics. Collaborations with pharmaceutical companies and government agencies are accelerating clinical trial activity. Research institutes also play a critical role in training oncologists and disseminating knowledge about personalized treatment approaches. As cancer prevalence rises, research institutes will remain at the forefront of innovation, driving rapid growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure and rising cancer prevalence globally, which has heightened demand for personalized oncology solutions. The U.S. leads in adoption of precision medicine, supported by strong R&D investments and favorable reimbursement policies. Major pharmaceutical companies and research institutes are headquartered in the region, driving innovation. Regulatory agencies such as the FDA provide fast-track approvals for breakthrough therapies, further boosting adoption. The region's dominance is expected to persist, supported by ongoing innovation and strong healthcare spending.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rapid healthcare digitization and rising cancer prevalence globally, particularly in emerging economies. Countries such as China, India, and Japan are witnessing increasing cancer incidence, creating urgent demand for personalized therapies. Governments are investing in oncology infrastructure and supporting clinical research initiatives. Growing collaborations between local institutes and global pharmaceutical companies are accelerating innovation. Rising disposable incomes and improving healthcare access are expanding patient adoption of advanced treatments. The region also benefits from increasing awareness of precision medicine and immunotherapy.

Key players in the market

Some of the key players in Personalized Oncology & Immunotherapy Market include Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, Gilead Sciences Inc., Amgen Inc., Regeneron Pharmaceuticals, BeiGene Ltd., Moderna Inc., BioNTech SE, Iovance Biotherapeutics, Bluebird Bio Inc. and Kite Pharma.

Key Developments:

In March 2026, Johnson & Johnson's Janssen unit introduced a personalized immunotherapy platform combining tumor-infiltrating lymphocytes (TILs) with AI-driven patient selection. The therapy targets advanced ovarian cancer, offering tailored immune responses. J&J's innovation reinforces its commitment to precision oncology, integrating cell therapy with digital health tools for improved patient outcomes.

In February 2026, Roche advanced its personalized oncology portfolio by launching a next-generation companion diagnostic platform integrated with its immunotherapy pipeline. The system enables real-time biomarker profiling for individualized treatment selection in breast and lung cancers. Roche's expansion into AI-driven diagnostics strengthens its leadership in precision oncology, aligning with its strategy to deliver tailored immunotherapy solutions across global markets.

In June 2025, Bristol-Myers Squibb expanded its immuno-oncology franchise with FDA approval of a novel PD-1 inhibitor combination therapy for advanced melanoma. The therapy leverages biomarker-driven patient stratification, enhancing survival outcomes. BMS continues to invest in personalized immunotherapy approaches, reinforcing its competitive edge in checkpoint inhibitor markets and broadening its reach in precision cancer care.

Therapy Types Covered:

  • Immune Checkpoint Inhibitors
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Monoclonal Antibodies
  • Targeted Small Molecule Therapy
  • Other Therapy Types

Biomarkers Covered:

  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Tumor Mutational Burden (TMB)
  • PD-L1 Expression
  • Other Biomarkers

Cancer Types Covered:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Hematologic Cancers
  • Other Cancer Types

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • PCR-Based Testing
  • Flow Cytometry
  • Gene Editing Technologies
  • Other Technologies

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Specialty Oncology Clinics
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Personalized Oncology & Immunotherapy Market, By Therapy Type

  • 5.1 Immune Checkpoint Inhibitors
  • 5.2 CAR-T Cell Therapy
  • 5.3 Cancer Vaccines
  • 5.4 Monoclonal Antibodies
  • 5.5 Targeted Small Molecule Therapy
  • 5.6 Other Therapy Types

6 Global Personalized Oncology & Immunotherapy Market, By Biomarker

  • 6.1 Genomic Biomarkers
  • 6.2 Proteomic Biomarkers
  • 6.3 Tumor Mutational Burden (TMB)
  • 6.4 PD-L1 Expression
  • 6.5 Other Biomarkers

7 Global Personalized Oncology & Immunotherapy Market, By Cancer Type

  • 7.1 Lung Cancer
  • 7.2 Breast Cancer
  • 7.3 Colorectal Cancer
  • 7.4 Melanoma
  • 7.5 Hematologic Cancers
  • 7.6 Other Cancer Types

8 Global Personalized Oncology & Immunotherapy Market, By Technology

  • 8.1 Next-Generation Sequencing (NGS)
  • 8.2 PCR-Based Testing
  • 8.3 Flow Cytometry
  • 8.4 Gene Editing Technologies
  • 8.5 Other Technologies

9 Global Personalized Oncology & Immunotherapy Market, By End User

  • 9.1 Hospitals
  • 9.2 Cancer Research Institutes
  • 9.3 Specialty Oncology Clinics
  • 9.4 Diagnostic Laboratories
  • 9.5 Other End Users

10 Global Personalized Oncology & Immunotherapy Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Roche Holding AG
  • 13.2 Bristol-Myers Squibb Company
  • 13.3 Merck & Co., Inc.
  • 13.4 Novartis AG
  • 13.5 Pfizer Inc.
  • 13.6 Johnson & Johnson
  • 13.7 AstraZeneca plc
  • 13.8 Gilead Sciences Inc.
  • 13.9 Amgen Inc.
  • 13.10 Regeneron Pharmaceuticals
  • 13.11 BeiGene Ltd.
  • 13.12 Moderna Inc.
  • 13.13 BioNTech SE
  • 13.14 Iovance Biotherapeutics
  • 13.15 Bluebird Bio Inc.
  • 13.16 Kite Pharma

List of Tables

  • Table 1 Global Personalized Oncology & Immunotherapy Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Personalized Oncology & Immunotherapy Market, By Therapy Type (2023-2034) ($MN)
  • Table 3 Global Personalized Oncology & Immunotherapy Market, By Immune Checkpoint Inhibitors (2023-2034) ($MN)
  • Table 4 Global Personalized Oncology & Immunotherapy Market, By CAR-T Cell Therapy (2023-2034) ($MN)
  • Table 5 Global Personalized Oncology & Immunotherapy Market, By Cancer Vaccines (2023-2034) ($MN)
  • Table 6 Global Personalized Oncology & Immunotherapy Market, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 7 Global Personalized Oncology & Immunotherapy Market, By Targeted Small Molecule Therapy (2023-2034) ($MN)
  • Table 8 Global Personalized Oncology & Immunotherapy Market, By Other Therapy Types (2023-2034) ($MN)
  • Table 9 Global Personalized Oncology & Immunotherapy Market, By Biomarker (2023-2034) ($MN)
  • Table 10 Global Personalized Oncology & Immunotherapy Market, By Genomic Biomarkers (2023-2034) ($MN)
  • Table 11 Global Personalized Oncology & Immunotherapy Market, By Proteomic Biomarkers (2023-2034) ($MN)
  • Table 12 Global Personalized Oncology & Immunotherapy Market, By Tumor Mutational Burden (TMB) (2023-2034) ($MN)
  • Table 13 Global Personalized Oncology & Immunotherapy Market, By PD-L1 Expression (2023-2034) ($MN)
  • Table 14 Global Personalized Oncology & Immunotherapy Market, By Other Biomarkers (2023-2034) ($MN)
  • Table 15 Global Personalized Oncology & Immunotherapy Market, By Cancer Type (2023-2034) ($MN)
  • Table 16 Global Personalized Oncology & Immunotherapy Market, By Lung Cancer (2023-2034) ($MN)
  • Table 17 Global Personalized Oncology & Immunotherapy Market, By Breast Cancer (2023-2034) ($MN)
  • Table 18 Global Personalized Oncology & Immunotherapy Market, By Colorectal Cancer (2023-2034) ($MN)
  • Table 19 Global Personalized Oncology & Immunotherapy Market, By Melanoma (2023-2034) ($MN)
  • Table 20 Global Personalized Oncology & Immunotherapy Market, By Hematologic Cancers (2023-2034) ($MN)
  • Table 21 Global Personalized Oncology & Immunotherapy Market, By Other Cancer Types (2023-2034) ($MN)
  • Table 22 Global Personalized Oncology & Immunotherapy Market, By Technology (2023-2034) ($MN)
  • Table 23 Global Personalized Oncology & Immunotherapy Market, By Next-Generation Sequencing (NGS) (2023-2034) ($MN)
  • Table 24 Global Personalized Oncology & Immunotherapy Market, By PCR-Based Testing (2023-2034) ($MN)
  • Table 25 Global Personalized Oncology & Immunotherapy Market, By Flow Cytometry (2023-2034) ($MN)
  • Table 26 Global Personalized Oncology & Immunotherapy Market, By Gene Editing Technologies (2023-2034) ($MN)
  • Table 27 Global Personalized Oncology & Immunotherapy Market, By Other Technologies (2023-2034) ($MN)
  • Table 28 Global Personalized Oncology & Immunotherapy Market, By End User (2023-2034) ($MN)
  • Table 29 Global Personalized Oncology & Immunotherapy Market, By Hospitals (2023-2034) ($MN)
  • Table 30 Global Personalized Oncology & Immunotherapy Market, By Cancer Research Institutes (2023-2034) ($MN)
  • Table 31 Global Personalized Oncology & Immunotherapy Market, By Specialty Oncology Clinics (2023-2034) ($MN)
  • Table 32 Global Personalized Oncology & Immunotherapy Market, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 33 Global Personalized Oncology & Immunotherapy Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.